Prognostic factors for the course of functional status of patients with ALS: a systematic review

Journal of Neurology

Volumn 262, Issue 6, 2015, Pages 1407-1423

  Creemers, Huub ^a   Grupstra, Hepke ^a   Nollet, Frans ^a   van den Berg, Leonard H ^b   Beelen, Anita ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Amyotrophic lateral sclerosis; Disease progression; Patient counseling; Prognosis

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; BODY MASS; COMORBIDITY; DETERIORATION; DISEASE COURSE; FOLLOW UP; FORCED VITAL CAPACITY; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL STATUS; HUMAN; MEDICAL ASSESSMENT; ONSET AGE; PREDICTIVE VALUE; PRIORITY JOURNAL; PUBLISHING; RATING SCALE; REVIEW; SYSTEMATIC REVIEW; DISABILITY; FACTUAL DATABASE; PATHOPHYSIOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

AMYOTROPHIC LATERAL SCLEROSIS; DATABASES, FACTUAL; DISABILITY EVALUATION; HUMANS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84931007882     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7564-8     Document Type: Review

References (47)

1. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299
2. Turner MR, Hardiman O, Benatar M, Brooks BR, Chiò A, de Carvalho M, Ince PG, Lin C, Miller RG, Mitsumoto H, Nicholson G, Ravits J, Shaw PJ, Swash M, Talbot K, Traynor BJ, Van den Berg LH, Veldink JH, Vucic S, Kiernan MC (2013) Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 12:310–322. doi:10.1016/S1474-4422(13)70036-X
3. Goldstein LH, Abrahams S (2013) Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 12:368–380. doi:10.1016/S1474-4422(13)70026-7
4. Ng L, Khan F (2009) Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 4:CD007425. doi:10.1002/14651858.CD007425.pub2
5. Scotton WJ, Scott KM, Moore DH, Almedom L, Wijesekera LC, Janssen A, Nigro C, Sakel M, Leigh PN, Shaw C, Al-Chalabi A (2012) Prognostic categories for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 13:502–508. doi:10.3109/17482968.2012.679281
6. Turner MR, Kiernan MC, Leigh PN, Talbot K (2009) Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 8:94–109. doi:10.1016/S1474-4422(08)70293-X
7. Altman DG (2001) Systematic reviews of evaluations of prognostic variables. BMJ 323:224–228
8. Hogden A, Greenfield D, Nugus P, Kiernan MC (2013) Development of a model to guide decision making in amyotrophic lateral sclerosis multidisciplinary care. Health Expect 23:1–14. doi:10.1111/hex.12169
9. The ALS CNTF treatment study (ACTS) phase I-II Study Group (1996) The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 53:141–147
10. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 169:13–21
11. Gordon PH, Miller RG, Moore DH (2004) ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord 5(Suppl 1):90–93
12. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B (2008) ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci 275:69–73. doi:10.1016/j.jns.2008.07.016
13. Hayden JA, Côté P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427–437
14. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C (2013) Assessing bias in studies of prognostic factors. Ann Intern Med 158:280–286. doi:10.7326/0003-4819-158-4-201302190-00009
15. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A (2011) GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 64:380–382. doi:10.1016/j.jclinepi.2010.09.011
16. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, Wozney L (2013) Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Syst Rev 2:71. doi:10.1186/2046-4053-2-71
17. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401–406. doi:10.1016/j.jclinepi.2010.07.015
18. Centre for Reviews and Dissemination York (2008) Systematic Reviews. CRD’s Guidance for undertaking reviews in Health Care. Systematic reviews of clinical tests; pp 109–156. Available at http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf
19. Gomeni R, Fava M, Pooled Resource Open-Access ALS Clinical Trials Consortium (2014) Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotemporal Degener 15:119–129. doi:10.3109/21678421.2013.838970
20. Clavelou P, Blanquet M, Peyrol F, Ouchchane L, Gerbaud L (2013) Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey. J Neurol Sci 331:126–131. doi:10.1016/j.jns.2013.06.002
21. Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, Wynne B, O’Brien C, Phukan J, Lynch C, Pender N, Hardiman O (2013) Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology 80:1590–1597. doi:10.1212/WNL.0b013e31828f18ac
22. Körner S, Kollewe K, Ilsemann J, Müller-Heine A, Dengler R, Krampfl K, Petri S (2013) Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol 20:647–654. doi:10.1111/ene.12015
23. Reich-Slotky R, Andrews J, Cheng B, Buchsbaum R, Levy D, Kaufmann P, Thompson JL (2013) Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 14:212–216. doi:10.3109/21678421.2013.77028
24. Paganoni S, Zhang M, Quiroz Zárate A, Jaffa M, Yu H, Cudkowicz ME, Wills AM (2012) Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 259:1923–1928. doi:10.1007/s00415-012-6440-7
25. Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, Lacomblez L, Meininger V (2010) Progression in ALS is not linear but is curvilinear. J Neurol 257:1713–1717. doi:10.1007/s00415-010-5609-1
26. Sorarù G, Ermani M, Logroscino G, Palmieri A, D’ Ascenzo C, Orsetti V, Volpe M, Cima V, Zara G, Pegoraro E, Angelini C (2010) Natural history of upper motor neuron-dominant ALS. Amyotroph Lateral Scler 11:424–429. doi:10.3109/17482960903300867
27. Qureshi M, Shui A, Dibernardo AB, Brown RH Jr, Schoenfeld DA, Cudkowicz ME (2008) Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 9:369–374. doi:10.1080/17482960802163614
28. Krampe H, Bartels C, Victorson D, Enders CK, Beaumont J, Cella D, Ehrenreich H (2008) The influence of personality factors on disease progression and health-related quality of life in people with ALS. Amyotroph Lateral Scler 9:99–107. doi:10.1080/17482960701875805
29. Rauchway AC, Kaiboriboon K, Bansal SK, Kulkantrakorn K, Guo X, Parks BJ, Hayat GR (2007) A role for functional classification in the early identification of prognostic factors in ALS. Amyotroph Lateral Scler 8:214–216
30. Qureshi MM, Hayden D, Urbinelli L, Ferrante K, Newhall K, Myers D, Hilgenberg S, Smart R, Brown RH, Cudkowicz ME (2006) Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler 7:173–182
31. De Carvalho M, Swash M (2006) Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis? Arch Neurol 63:557–560
32. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG, Eurals Consortium (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10:310–323. doi:10.3109/17482960802566824
33. Franchignoni F, Mora G, Giordano A, Volanti P, Chiò A (2013) Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry 84:1340–1345. doi:10.1136/jnnp-2012-304701
34. Grimby G, Tennant A, Tesio L (2012) The use of raw scores from ordinal scales: time to end malpractice? J Rehabil Med 44:97–98. doi:10.2340/16501977-0938
35. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955. doi:10.1016/S0140-6736(10)61156-7
36. Ravits JM, La Spada AR (2009) ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 8(73):805–811. doi:10.1212/WNL.0b013e3181b6bbbd
37. Su XW, Broach JR, Connor JR, Gerhard GS, Simmons Z (2014) Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. Muscle Nerve 49:786–803. doi:10.1002/mus.24198
38. Ganesalingam J, Stahl D, Wijesekera L, Galtrey C, Shaw CE, Leigh PN, Al-Chalabi A (2009) Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS One 4(9):e7107. doi:10.1371/journal.pone.0007107
39. Talman P, Forbes A, Mathers S (2009) Clinical phenotypes and natural progression for motor neuron disease: analysis from an Australian database. Amyotroph Lateral Scler 10:79–84. doi:10.1080/17482960802195871
40. Chiò A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group, (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82:740–746. doi:10.1136/jnnp.2010.235952
41. Sabatelli M, Zollino M, Luigetti M, Grande AD, Lattante S, Marangi G, Monaco ML, Madia F, Meleo E, Bisogni G, Conte A (2011) Uncovering amyotrophic lateral sclerosis phenotypes: clinical features and long-term follow-up of upper motor neuron-dominant ALS. Amyotroph Lateral Scler 12:278–282. doi:10.3109/17482968.2011.580849
42. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain 135(Pt 3):847–852. doi:10.1093/brain/awr351
43. Bedlack RS (2013) The importance of functional assessment in amyotrophic lateral sclerosis: a Clinical Review. Neurology reviews [Supplement];S1–S4. URL: http://www.neurologyreviews.com/fileadmin/qhi_archive/ArticlePDF/NR/0210100S1.pdf
44. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G (1997) Language bias in randomised controlled trials published in English and German. Lancet 350:326–329
45. Moher D, Fortin P, Jadad AR, Jüni P, Klassen T, Le Lorier J, Liberati A, Linde K, Penna A (1996) Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 347:363–366
46. Voustianiouk A, Seidel G, Panchal J, Sivak M, Czaplinski A, Yen A, Appel SH, Lange DJ (2008) ALSFRS and appel ALS scores: discordance with disease progression. Muscle Nerve 37:668–672. doi:10.1002/mus.20977
47. Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, Malats N, Briggs A, Schroter S, Altman DG, Hemingway H PROGRESS Group (2013) Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 10:e1001380. doi:10.1371/journal.pmed.1001380